Literature DB >> 1748299

Synthesis and functional characterization of a recombinant monoclonal antibody directed against the alpha-chain of the human interleukin-2 receptor.

B Kaluza1, H Lenz, E Russmann, H Hock, O Rentrop, O Majdic, W Knapp, U H Weidle.   

Abstract

We have determined the sequence of the light and heavy chains of mAb 3G-10 (IgG1), a monoclonal antibody competing with interleukin 2 (IL2) for binding to the human IL2 receptor Tac protein. The antibody-encoding genes were chimerized by introducing splice donor and part of the intron sequences into the cDNA and subsequently linking it to the constant parts of the human IgG1 gene. The chimeric mAb was produced in mouse myeloma cells and purified. Murine and chimeric mAbs showed similar properties with respect to inhibition of T-cell proliferation. In contrast to its murine counterpart, the chimeric mAb exhibited Ab-dependent cellular cytotoxicity and, when combined with an Ab recognizing a different epitope on the IL2 receptor Tac protein, was able to activate human complement. The chimerized mAb might therefore have improved therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748299     DOI: 10.1016/0378-1119(91)90330-e

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  3 in total

1.  Expression of recombinant antibody and secreted alkaline phosphatase in mammalian cells. Influence of cell line and culture system upon production kinetics.

Authors:  A J Racher; J L Moreira; P M Alves; M Wirth; U H Weidle; H Hauser; M J Carrondo; J B Griffiths
Journal:  Appl Microbiol Biotechnol       Date:  1994-02       Impact factor: 4.813

2.  Cultural and physiological factors affecting expression of recombinant proteins.

Authors:  J B Griffiths; A J Racher
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

3.  Selective Targeting of IL-15Rα Is Sufficient to Reduce Inflammation.

Authors:  Dihia Meghnem; Mike Maillasson; Isabelle Barbieux; Sébastien Morisseau; Dalloba Keita; Yannick Jacques; Agnès Quéméner; Erwan Mortier
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.